DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson’s disease-Reference-Cited by-同舟云学术

DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson’s disease

Published:2024-06-11 Issue:1 Volume:13 Page:
ISSN:2047-9158
Container-title:Translational Neurodegeneration
language:en
Short-container-title:Transl Neurodegener

Author:

Appleton Ellen,Khosousi Shervin,Ta Michael,Nalls Michael,Singleton Andrew B.,Sturchio Andrea,Markaki Ioanna,Paslawski Wojciech,Iwaki Hirotaka,Svenningsson Per^ORCID

Funder

Knut och Alice Wallenbergs Stiftelse

NHLBI Division of Intramural Research

Science for Life Laboratory

Kommunfullmäktige, Stockholms Stad

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s40035-024-00421-0.pdf

Reference8 articles.

1. Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284–303.

2. Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, et al. Assessment of heterogeneity among participants in the Parkinson’s progression markers initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407–17.

3. Paslawski W, Khosousi S, Hertz E, Markaki I, Boxer A, Svenningsson P. Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease. Transl Neurodegener. 2023;12(1):42.

4. Pereira JB, Kumar A, Hall S, Palmqvist S, Stomrud E, Bali D, et al. DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nat Aging. 2023;3(10):1201–9.

5. Del Campo M, Vermunt L, Peeters CFW, Sieben A, Hok AHYS, Lleó A, et al. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer’s disease. Nat Commun. 2023;14(1):5635.